Osteoporosis Management in Individuals Over 80

Introduction to Osteoporosis Treatment

The American College of Physicians recommends oral bisphosphonates (alendronate or risedronate) as the first-line pharmacological treatment for individuals over 80 with osteoporosis, combined with calcium and vitamin D supplementation, weight-bearing exercise, and fall prevention strategies 1

The National Osteoporosis Foundation suggests performing initial fracture risk assessment using bone mineral density (BMD) via dual-energy x-ray absorptiometry (DXA) with vertebral fracture assessment (VFA) or spinal x-rays 2
Calculate 10-year fracture risk using FRAX for patients ≥40 years, though recognize this tool may underestimate risk in very elderly patients with multiple falls or frailty 2
Reassess fracture risk clinically every 12 months and consider BMD testing every 1-3 years depending on risk factors 1

The American Geriatrics Society recommends calcium supplementation of 1,000-1,200 mg elemental calcium daily through diet and supplements if dietary intake is insufficient 1
Vitamin D supplementation of 800 IU daily is recommended to maintain serum 25(OH)D levels ≥30 ng/mL 1
Regular weight-bearing exercises and resistance training, plus balance exercises, are recommended for all patients over 80 1

The Endocrine Society strongly recommends oral bisphosphonates (alendronate or risedronate) as initial therapy for patients at high or very high fracture risk (T-score ≤-2.5, prior vertebral/hip fracture, or high FRAX score ≥20% for major osteoporotic fracture) 1
Intravenous zoledronic acid (annual infusion) or denosumab (subcutaneous injection every 6 months) may be considered as second-line options if oral bisphosphonates are not appropriate 1
Denosumab requires sequential therapy with bisphosphonates upon discontinuation to prevent rebound bone loss and vertebral fractures 2

Orthogeriatric co-management is recommended for frail elderly patients with multiple comorbidities and polypharmacy 1
Medication choice may require adjustment in renal impairment 1
Balance benefits of fracture prevention against potential medication side effects in very elderly patients 1
Home safety assessment and modifications, as well as review of medications that increase fall risk, are recommended to prevent falls 3, 2
Vision and hearing assessment are also recommended to prevent falls 2

Regular monitoring for medication tolerance and adherence is essential, and patient education about disease burden, risk factors, and treatment importance is critical 1
Fracture liaison services may increase medication initiation and adherence, and reduce subsequent fractures 1

Anabolic agents (teriparatide, romosozumab) are typically used for 1-2 years, followed by transition to antiresorptive therapy 2
Denosumab and romosozumab require sequential antiresorptive therapy to prevent rebound bone loss 2